Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics

Award Number: K22CA279077
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 12/01/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics - PROJECT SUMMARY Shenqqing (Stan) Gu, Ph.D., is an experimental-computational biologist whose career goal is to develop personalized strategies for optimal combination immunotherapy to cure cancer. Titled “Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics”, the proposed research seeks to elucidate the context dependencies of SMAC mimetics’ effects and examine its optimal combination with existing immune checkpoint blockade therapy. Career development plan: Dr. Gu is a recipient of Sara Elizabeth O’Brien Trust Fellowship. His previous work has focused on the regulation of cancer-immune interaction, using various approaches including clonal tracing, data mining, and genome-wide CRISPR screening, which have prepared him to conduct the proposed research. Dr. Gu has outlined specific training activities to expand his skill set in four areas: 1) T cell biology, 2) machine learning, 3) single-cell technologies, 4) leadership and professional skills. This skill set is necessary to succeed in my independent research career. Collaborators/Environment: Dr. Gu’s collaboration team assembles world-leading experts in cancer immunology, computational biology, translational and clinical research, melanoma, and single-cell technology. Leveraging the extensive collaboration resources at DFCI, Harvard, and NCI, and access to a large amount of clinical samples, Dr. Gu is uniquely placed to identify the optimal usage of SMAC mimetics to enhance the efficacy of immunotherapy of cancer. Research: Our previous research identified that SMAC mimetics can upregulate MHC-I in some cancer cells and potentiate immunotherapy, but it is unclear which subset of cancer patients can benefit from SMAC mimetic treatment. To facilitate effective use of SMAC mimetics in the clinic, this proposal will interrogate SMAC mimetics regarding the optimal contexts of gene regulation and rational combination with immune checkpoint blockade. Aim 1 will integrate genetic/epigenetic feature selection and functional validation to identify the context dependencies of SMAC mimetics’ effects on cancer cells. Aim 2 will integrate multi-omic profiling at single-cell level to examine the effects of SMAC mimetic treatment on immune cells. Aim 3 will evaluate the efficacy of different scheduling of combination of SMAC mimetics and ICB using in vitro co-culture and in vivo transplantation models. Outcomes/Impact: This project will reveal the genetic/epigenetic context dependencies of SMAC mimetics’ effects, elucidate their effects on immune cells, and examine the optimal combination with immunotherapy. Data from this study can help improve the design of clinical trials testing SMAC mimetics in cancer patients. The development career transition award will enable Dr. Gu to become a leader in the new field of developing personalized combination immunotherapy strategies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $192,240 )
2026	2026	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	000	3	12/11/2025	NON-COMPETING CONTINUATION	$173,016
2026	2026	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	001	3	4/16/2026	NON-COMPETING CONTINUATION	$19,224
														Subtotal = $192,240

Issue Date FY: 2025 ( Subtotal = $192,240 )
2025	2025	THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	000	2	11/1/2024	NON-COMPETING CONTINUATION	$192,240
														Subtotal = $192,240

Issue Date FY: 2024 ( Subtotal = $192,240 )
2024	2024	UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	000	1	11/14/2023	NEW	$192,240
														Subtotal = $192,240

Grand Total All Awards = $576,720

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics

Award Number: K22CA279077

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 12/01/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer